| Chronic Kidney Diseases
Synjardy vs Renvela
Side-by-side clinical, coverage, and cost comparison for chronic kidney diseases.Deep comparison between: Synjardy vs Renvela with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsRenvela has a higher rate of injection site reactions vs Synjardy based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Renvela but not Synjardy, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Synjardy
Renvela
At A Glance
Oral
Once or twice daily
SGLT2 inhibitor / biguanide
Oral
Three times daily with meals
Phosphate binder
Indications
- Diabetes Mellitus, Non-Insulin-Dependent
- Cardiovascular Diseases
- Congestive heart failure
- Chronic Kidney Diseases
- Chronic Kidney Diseases
Dosing
Diabetes Mellitus, Non-Insulin-Dependent SYNJARDY: empagliflozin 10 mg/day (may increase to 25 mg/day) plus metformin HCl up to 2,000 mg/day, taken orally twice daily with meals; SYNJARDY XR: once daily with morning meal; not recommended if eGFR <45 mL/min/1.73 m2.
Cardiovascular Diseases, Congestive heart failure, Chronic Kidney Diseases Empagliflozin 10 mg/day component as part of SYNJARDY or SYNJARDY XR, taken orally; not recommended if eGFR <45 mL/min/1.73 m2.
Chronic Kidney Diseases (Adults) Starting dose 0.8-1.6 g orally three times daily with meals based on serum phosphorus level; titrate by 0.8 g per meal at two-week intervals to achieve target serum phosphorus.
Chronic Kidney Diseases (Pediatric, >=6 years) Starting dose 0.8-1.6 g three times daily with meals based on body surface area (BSA) category; titrate based on BSA category at two-week intervals for 6 weeks then every 4 weeks as needed.
Contraindications
- Severe renal impairment (eGFR <30 mL/min/1.73 m2)
- Acute or chronic metabolic acidosis, including diabetic ketoacidosis
- Hypersensitivity to empagliflozin, metformin HCl, or any excipient in SYNJARDY or SYNJARDY XR
- Bowel obstruction
- Known hypersensitivity to sevelamer carbonate, sevelamer hydrochloride, or any excipient
Adverse Reactions
Most common (>=5%) Hypoglycemia (with sulfonylurea), urinary tract infection, nasopharyngitis, diarrhea, nausea/vomiting, flatulence, abdominal discomfort, indigestion, asthenia, headache
Serious Lactic acidosis, diabetic ketoacidosis, volume depletion, urosepsis, pyelonephritis, necrotizing fasciitis of the perineum (Fournier's gangrene), hypersensitivity reactions, vitamin B12 deficiency, lower limb amputation
Postmarketing Constipation, necrotizing fasciitis of the perineum, urosepsis, pyelonephritis, ketoacidosis, acute kidney injury, angioedema, rash, urticaria, cholestatic/hepatocellular liver injury
Most common (>5%) Vomiting, nausea, diarrhea, dyspepsia, abdominal pain, flatulence, constipation
Postmarketing Hypersensitivity, pruritus, rash, abdominal pain, bleeding gastrointestinal ulcers, colitis, ulceration, necrosis, fecal impaction, ileus, intestinal obstruction, intestinal perforation
Pharmacology
Empagliflozin is an SGLT2 inhibitor that reduces renal reabsorption of filtered glucose, lowers the renal threshold for glucose, and increases urinary glucose excretion; metformin HCl is a biguanide antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.
Sevelamer carbonate is a non-absorbed phosphate-binding cross-linked polymer, free of metal and calcium, that binds phosphate in the gastrointestinal tract via ionic and hydrogen bonding, thereby decreasing phosphate absorption and lowering serum phosphorus concentrations.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Synjardy
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (9/12) · Qty limit (11/12)
Renvela
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (4/12) · Qty limit (9/12)
UnitedHealthcare
Synjardy
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (7/8)
Renvela
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Synjardy
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Renvela
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Synjardy.
No savings programs available for Renvela.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
SynjardyView full Synjardy profile
RenvelaView full Renvela profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.